Requip and Haemarthrosis - a phase IV clinical study of FDA data

Summary:

Haemarthrosis is reported only by a few people who take Requip.

The phase IV clinical study analyzes which people take Requip and have Haemarthrosis. It is created by eHealthMe based on reports of 21,035 people who have side effects while taking Requip from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

21,035 people reported to have side effects when taking Requip.
Among them, 4 people (0.02%) have Haemarthrosis.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,097 Requip users for its effectiveness, alternative drugs and more.

What is Haemarthrosis?

Haemarthrosis (haemarthrosis is where blood is able to enter the joint capsule) is found to be associated with 1,171 drugs and 710 conditions by eHealthMe.

Number of Requip and Haemarthrosis reports submitted per year:

Gender of people who have Haemarthrosis when taking Requip *:

female: 0.0 %
male: 100 %

Age of people who have Haemarthrosis when taking Requip *:

Common drugs people take besides Requip *:

Common side effects people have besides Haemarthrosis *:

Pneumonia: 1 person, 25.00%
Pco2 Increased: 1 person, 25.00%
Oedema Peripheral (superficial swelling): 1 person, 25.00%
Head Injury: 1 person, 25.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 25.00%
Arthritis Infective (purulent invasion of a joint by an infectious agent which produces arthritis): 1 person, 25.00%

Common conditions people have *:

Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 50.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 25.00%
Embolism Venous (embolus may pass into the arterial system): 1 person, 25.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 25.00%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Requip and have Haemarthrosis?

Check whether Haemarthrosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Haemarthrosis and when was it recovered:

Haemarthrosis in Requip

Expand to all the drugs that have ingredients of ropinirole hydrochloride:

Haemarthrosis and drugs with ingredients of ropinirole hydrochloride

Alternative drugs to, pros and cons of Requip:

Requip (22,097 reports)

Common Requip side effects:

Drug ineffective: 1,870 reports
Fatigue (feeling of tiredness): 1,331 reports
Drowsiness: 1,164 reports
Dizziness: 1,134 reports
Pain: 1,033 reports

Browse all side effects of Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Haemarthrosis treatments and more:

Haemarthrosis (7,958 reports)

COVID vaccines that are related to Haemarthrosis:

Common drugs associated with Haemarthrosis:

All the drugs that are associated with Haemarthrosis:

Haemarthrosis (1,171 drugs)

Common conditions associated with Haemarthrosis:

Atrial fibrillation/flutter: 570 reports
Stroke: 357 reports
Preventive health care: 274 reports

All the conditions that are associated with Haemarthrosis:

Haemarthrosis (710 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ropinirole hydrochloride (the active ingredients of Requip) and Requip (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.